Viewing nowCombinationDucaem Tablet 30/2.5 mg
Fimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Mothers Pharmaceutical

MFDS item code 202300086 · Approved 2023.01.06 · Insurance code 622804930
Treatment of essential hypertension not adequately controlled with fimasartan monotherapy
This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with Pimasartan Potassium. It helps to effectively lower blood pressure and manage hypertension.
Adults The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using fimasartan; however, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 60/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or this medicine 60/2.5 mg. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Older adults No initial dose adjustment is required for older adults aged 70 years or younger. Patients with renal impairment No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 mg in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine have not been established in children and adolescents aged 18 years or younger.
This drug can cause serious harm or death to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. This drug should not be administered to certain patients. For example, individuals allergic to this drug's components or similar drugs, pregnant or breastfeeding women, patients undergoing renal dialysis, individuals with severe liver impairment or biliary obstruction, certain genetically lactose intolerant patients, severe aortic stenosis patients, and patients in shock are prohibited from using it. Patients with low blood volume or salt deficiency, impaired renal function, renal artery hypertension, aortic and mitral valve stenosis, primary hyperaldosteronism, severe hypotension, elderly patients, and individuals allergic to certain dyes in this drug should use it cautiously. When taking this drug, side effects such as dizziness, headache, facial swelling, urination disorders, insomnia, and flushing may occur. Rarely, serious kidney issues, blood pressure drop, and allergic reactions may occur, so if any unusual symptoms arise, consult medical staff immediately. This drug lowers blood pressure, so patients with hypotension or electrolyte imbalance must correct their condition before taking it and monitor blood pressure and electrolyte status regularly during treatment. Patients with heart failure or kidney issues are at risk of hyperkalemia, so potassium levels must be managed through blood tests. When used with other antihypertensive agents, the blood pressure-lowering effect may be enhanced, so interactions with other medications should be carefully managed. Additionally, there may be a risk of worsening renal function when combined with certain medications, necessitating regular testing. Pregnant or breastfeeding women should avoid taking this drug unless discussed with healthcare providers. The safety and efficacy of this drug have not been established in children under 18 years of age, so its use in pediatric patients is not recommended. For the elderly, no special dose adjustment is needed, but some patients may respond more sensitively to the medication, so caution is advised. It is advised not to use this drug in patients with severe liver impairment. In case of overdose, symptoms may include hypotension, cardiac arrhythmias, and severe vasodilation, so one should visit a medical facility immediately for appropriate treatment. This drug should be stored out of reach of children and should not be transferred to other containers. During treatment, drowsiness or dizziness may occur, so caution is required when driving or operating hazardous machinery.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a tightly closed container that blocks light. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature.
White, rounded square film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Mothers Pharmaceutical
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.